Stomach cancer laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 2: | Line 2: | ||
{{Stomach cancer}} | {{Stomach cancer}} | ||
{{CMG}}; {{AE}} {{MAD}} | {{CMG}}; {{AE}} {{MAD}} | ||
==Overview== | |||
[[Laboratory]] findings in [[gastric cancer]] include [[anemia]] of [[chronic disease]] on [[complete blood count]], [[liver function tests]] may reveal [[abnormalities]] in [[liver function tests]], [[antigens]] such as [[carcinoembryonic antigen]], [[CA-125|glycoprotein CA 125]], [[CA19-9|carbohydrate antigen 19-9]], [[cancer]] [[antigen]] 72-4, [[alpha-fetoprotein]]. | |||
==Stomach cancer laboratory findings== | == Stomach cancer laboratory findings == | ||
* A [[Complete blood count|complete blood cell count]] shows [[anemia]] of [[chronic disease]]. | |||
A complete blood cell count | |||
* [[Liver function tests]] may be disturbed in [[patients]] with [[liver]] [[metastasis]]. | |||
Carcinoembryonic antigen (CEA) is | * [[Carcinoembryonic antigen]] ([[CEA]]) is elevated in 50% of [[patients]]. A drop in an elevated level of [[CEA]] means response to preoperative [[therapy]] but it is not sensitive or specific. | ||
* [[CA-125|Glycoprotein CA 125]] antigen may be elevated.<ref name="pmid280023202">{{cite journal| author=Luo T, Chen W, Wang L, Zhao H| title=CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study. | journal=Medicine (Baltimore) | year= 2016 | volume= 95 | issue= 51 | pages= e5297 | pmid=28002320 | doi=10.1097/MD.0000000000005297 | pmc=5181804 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28002320 }}</ref> | |||
* [[CA19-9|Carbohydrate antigen 19-9]] ([[CA 19-9]]) is elevated.<ref name="pmid18821070">{{cite journal| author=Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M| title=Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. | journal=Adv Ther | year= 2008 | volume= 25 | issue= 10 | pages= 1075-84 | pmid=18821070 | doi=10.1007/s12325-008-0100-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18821070 }}</ref> | |||
* [[Cancer]] [[antigen]] 72-4 (CA72-4) may be elevated.<ref name="pmid7874576">{{cite journal| author=Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F et al.| title=CA 72-4 serum marker--a new tool in the management of carcinoma patients. | journal=Cancer Invest | year= 1995 | volume= 13 | issue= 2 | pages= 227-38 | pmid=7874576 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7874576 }}</ref> | |||
* [[Alpha-fetoprotein]] ([[Alpha-fetoprotein|AFP]]) may be elevated.<ref name="pmid12435906">{{cite journal| author=Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H et al.| title=Clinicopathologic features of gastric cancers producing alpha-fetoprotein. | journal=Dig Surg | year= 2002 | volume= 19 | issue= 5 | pages= 359-65; discussion 365 | pmid=12435906 | doi=10.1159/000065838 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12435906 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
| Line 36: | Line 27: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Conditions diagnosed by stool test]] | [[Category:Conditions diagnosed by stool test]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 00:18, 30 July 2020
|
Stomach cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Stomach cancer laboratory findings On the Web |
|
American Roentgen Ray Society Images of Stomach cancer laboratory findings |
|
Risk calculators and risk factors for Stomach cancer laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Laboratory findings in gastric cancer include anemia of chronic disease on complete blood count, liver function tests may reveal abnormalities in liver function tests, antigens such as carcinoembryonic antigen, glycoprotein CA 125, carbohydrate antigen 19-9, cancer antigen 72-4, alpha-fetoprotein.
Stomach cancer laboratory findings
- A complete blood cell count shows anemia of chronic disease.
- Liver function tests may be disturbed in patients with liver metastasis.
- Carcinoembryonic antigen (CEA) is elevated in 50% of patients. A drop in an elevated level of CEA means response to preoperative therapy but it is not sensitive or specific.
- Glycoprotein CA 125 antigen may be elevated.[1]
- Carbohydrate antigen 19-9 (CA 19-9) is elevated.[2]
- Cancer antigen 72-4 (CA72-4) may be elevated.[3]
- Alpha-fetoprotein (AFP) may be elevated.[4]
References
- ↑ Luo T, Chen W, Wang L, Zhao H (2016). "CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study". Medicine (Baltimore). 95 (51): e5297. doi:10.1097/MD.0000000000005297. PMC 5181804. PMID 28002320.
- ↑ Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M (2008). "Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer". Adv Ther. 25 (10): 1075–84. doi:10.1007/s12325-008-0100-4. PMID 18821070.
- ↑ Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F; et al. (1995). "CA 72-4 serum marker--a new tool in the management of carcinoma patients". Cancer Invest. 13 (2): 227–38. PMID 7874576.
- ↑ Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H; et al. (2002). "Clinicopathologic features of gastric cancers producing alpha-fetoprotein". Dig Surg. 19 (5): 359–65, discussion 365. doi:10.1159/000065838. PMID 12435906.